{ "schemaVersion": 1, "organisationId": "O-e9ec519ce00344a3a9fce8f24ac0f870", "slug": "illumina-inc", "name": "ILLUMINA, INC.", "updatedAt": "2026-10-04T09:52:57.778927Z", "sections": [ { "type": "OVERVIEW", "text": "Illumina, Inc. is a global life-sciences company focused on sequencing- and array-based solutions for genetic and genomic analysis, serving research and clinical markets. Its portfolio includes sequencing and microarray systems, consumables, and analysis tools. The company states its mission is “Improving human health by unlocking the power of the genome.” [P35858313][P2461814][https://www.illumina.com/company/about-us/corporate-social-responsibility.html]\n\nIllumina markets and distributes products across the Americas, Europe, and Asia-Pacific, with international shipments accounting for 48% of FY2025 revenue. For the fiscal year ended December 28, 2025, it reported $4.343 billion in consolidated revenue and approximately 8,600 full-time employees. [P72883791][P17682324][P38798731][T13228864]\n[P35858313][P2461814][P72883791][P17682324][P38798731][T13228864][https://www.illumina.com/company/about-us/corporate-social-responsibility.html]", "updatedAt": "2026-10-04T09:52:57.778927Z" }, { "type": "PRODUCTS", "text": "Illumina’s product portfolio includes high-throughput and benchtop sequencing systems, sequencing consumables, microarrays, informatics software and instrument services. Its sequencing platforms support applications from amplicon and targeted-panel sequencing to whole-genome and population-scale studies, with reported output ranging from about 500 Mb to 16 Tb per run depending on instrument and application. [P48863762][P100287799]\n\nThe production-scale NovaSeq X Series is designed for high-throughput sequencing; published specifications list up to 8–10.5 Tb per run for NovaSeq X and 16–21 Tb for NovaSeq X Plus, read lengths up to 2 × 300 bp, and run times of 14–48 hours. The benchtop MiSeq i100 Series lists 1.5–30 Gb per run and run times as short as four hours, with room-temperature reagents. NextSeq 1000/2000 systems support read lengths from 1 × 50 bp to 2 × 300 bp. Output and run time vary by instrument and configuration. [https://www.illumina.com/systems/sequencing-platforms/novaseq-x-plus/specifications.html][https://www.illumina.com/systems/sequencing-platforms/miseq-i100/specifications.html][https://www.illumina.com/systems/sequencing-platforms/nextseq-1000-2000.html] Illumina also offers sequencing kits and reagents, microarray products, and software including BaseSpace for sequencing data management and analysis, DRAGEN for secondary analysis, and Connected Analytics for cloud-based data management and analysis. Its services include instrument service plans, qualification and training. [https://emea.illumina.com/products/by-type/sequencing-kits.html][P84488577][P107729460][P57346774][https://www.illumina.com/services/instrument-services.html]\n\nIn fiscal 2025, consumables accounted for $3.227 billion (74.3%) of $4.343 billion in revenue, instruments $482 million (11.1%), and service and other $634 million (14.6%). Sequencing revenue was $3.985 billion, while microarray revenue was $358 million. [T12402378] In the first half of 2026, consumables represented $1.649 billion of $2.251 billion in revenue (73.3%), instruments $250 million (11.1%), and service and other $352 million (15.6%). [T16635174]\n[P48863762][P100287799][P84488577][P107729460][P57346774][T12402378][T16635174][https://www.illumina.com/systems/sequencing-platforms/novaseq-x-plus/specifications.html][https://www.illumina.com/systems/sequencing-platforms/miseq-i100/specifications.html][https://www.illumina.com/systems/sequencing-platforms/nextseq-1000-2000.html][https://emea.illumina.com/products/by-type/sequencing-kits.html][https://www.illumina.com/services/instrument-services.html]", "updatedAt": "2026-10-04T09:52:57.778927Z" }, { "type": "GEOGRAPHY", "text": "For fiscal 2025, Illumina reported revenue of $4.343 billion across four regions: Americas, $2.406 billion (55.4%); Europe, $1.264 billion (29.1%); Greater China, $243 million (5.6%); and Asia-Pacific, Middle East and Africa, $430 million (9.9%). Percentages are calculated from the reported regional revenues and total. [T4802710] Shipments outside the United States represented 48% of revenue in 2025. Illumina markets directly in North America, Europe, Latin America and Asia-Pacific, and uses distributors in certain markets across Europe, Asia-Pacific, Latin America, the Middle East and Africa. [P17682324][P72883791] Its international sales offices are described as located throughout Europe, Asia-Pacific and Brazil. [P8036207]\n\nThe company’s listed leased facilities include San Diego, California (860,000 sq. ft.); Singapore (564,000); Cambridge, UK (181,000); the San Francisco Bay Area, California (166,000); Madison, Wisconsin (133,000); Eindhoven, Netherlands (90,000); China (86,000); and India (66,000). The listed uses include offices, laboratories, manufacturing and distribution; manufacturing facilities are identified in San Diego, the San Francisco Bay Area, Madison, Cambridge and Singapore. [T728442][P30921653] Illumina’s principal executive offices are in San Diego, California. [P35858313]\n\nAs of December 28, 2025, Illumina reported approximately 4,740 employees in the Americas, 1,280 in Europe, 2,350 in Africa, the Middle East and Asia, and 290 in Greater China. [P38798731]\n[T4802710][T4802710][T4802710][T4802710][T4802710][P17682324][P72883791][P8036207][T728442][P30921653][P35858313][P38798731]", "updatedAt": "2026-10-04T09:52:57.778927Z" }, { "type": "SEGMENTS", "text": "For FY2025, Illumina reported one reportable segment, **Core Illumina**, which represented 100% of consolidated revenue: $4.343 billion. The company’s current segment reporting excludes GRAIL, which was spun off in June 2024. [P66846235][T13228864] Core Illumina is the genomics business, with activity spanning sequencing and microarray products and applications; the company describes focus areas including sequencing-based research and translational and clinical markets such as oncology, genetic health and reproductive health. These are product and market areas, not separately reported segments. [P119549994][P4189507][T12402378]\n\nIllumina also disaggregates revenue by product category and technology, but these are not additional reportable segments. In FY2025, consumables generated $3.227 billion (approximately 74.3% of consolidated revenue), instruments $482 million (11.1%), and services and other $634 million (14.6%). By technology, sequencing generated $3.985 billion (91.8%) and microarray $358 million (8.2%). [T13228864][T12402378]\n[P66846235][T13228864][P119549994][P4189507][T12402378][T13228864][T13228864][T13228864][T13228864][T12402378][T12402378]", "updatedAt": "2026-10-04T09:52:57.778927Z" }, { "type": "HISTORY", "text": "Illumina was founded in San Diego in April 1998. In 2006, it announced the acquisition of Solexa and reached the Genome Analyzer milestone; the Solexa acquisition was completed in early 2007. The company subsequently announced the HiSeq 2000 in 2010 and MiSeq in 2011. [https://www.illumina.com/company/news-center/press-releases/2023/c149a755-79b1-4040-b0f5-4aa7d6b15320.html][https://www.illumina.com/content/dam/illumina-marketing/documents/company/illumina-source-book-september-2020.pdf][https://www.illumina.com/science/technology/next-generation-sequencing/illumina-sequencing-history.html][https://emea.illumina.com/company/news-center/press-releases/2010/1374339.html][https://emea.illumina.com/company/news-center/press-releases/2011/1515239.html] In 2013, Illumina completed its acquisition of Verinata Health. [https://emea.illumina.com/company/news-center/press-releases/2013/1787718.html]\n\nIn 2016, Illumina formed GRAIL to develop blood-based cancer screening, and Francis deSouza became president and CEO, succeeding Jay Flatley. [https://emea.illumina.com/company/news-center/press-releases/2016/2127903.html][https://www.illumina.com/company/news-center/press-releases/press-release-details.html?newsid=26816] Illumina acquired GRAIL in 2021 and completed its spin-off as a separate, publicly traded company in 2024. [P21859633][P23498362] In 2023, Jacob Thaysen was appointed CEO, effective September 25. [https://www.illumina.com/company/news-center/press-releases/press-release-details.html?newsid=59115c59-ad0c-49dd-86d3-a9c00df0c847]\n[P21859633][P23498362][https://www.illumina.com/company/news-center/press-releases/2023/c149a755-79b1-4040-b0f5-4aa7d6b15320.html][https://www.illumina.com/content/dam/illumina-marketing/documents/company/illumina-source-book-september-2020.pdf][https://www.illumina.com/science/technology/next-generation-sequencing/illumina-sequencing-history.html][https://emea.illumina.com/company/news-center/press-releases/2010/1374339.html][https://emea.illumina.com/company/news-center/press-releases/2011/1515239.html][https://emea.illumina.com/company/news-center/press-releases/2013/1787718.html][https://emea.illumina.com/company/news-center/press-releases/2016/2127903.html][https://www.illumina.com/company/news-center/press-releases/press-release-details.html?newsid=26816][https://www.illumina.com/company/news-center/press-releases/press-release-details.html?newsid=59115c59-ad0c-49dd-86d3-a9c00df0c847]", "updatedAt": "2026-10-04T09:52:57.778927Z" } ], "sources": [ { "id": "P35858313", "href": "https://app.finbar.com/go?id=P35858313", "label": "ILLUMINA, INC. — Full financial report (2025 Y)", "documentId": "D-f70506775ed346c3a83059b1c1551e43" }, { "id": "P2461814", "href": "https://app.finbar.com/go?id=P2461814", "label": "ILLUMINA, INC. — Full financial report (2025 Y)", "documentId": "D-f70506775ed346c3a83059b1c1551e43" }, { "id": "https://www.illumina.com/company/about-us/corporate-social-responsibility.html", "href": "https://www.illumina.com/company/about-us/corporate-social-responsibility.html", "label": "www.illumina.com" }, { "id": "P72883791", "href": "https://app.finbar.com/go?id=P72883791", "label": "ILLUMINA, INC. — Full financial report (2025 Y)", "documentId": "D-f70506775ed346c3a83059b1c1551e43" }, { "id": "P17682324", "href": "https://app.finbar.com/go?id=P17682324", "label": "ILLUMINA, INC. — Full financial report (2025 Y)", "documentId": "D-f70506775ed346c3a83059b1c1551e43" }, { "id": "P38798731", "href": "https://app.finbar.com/go?id=P38798731", "label": "ILLUMINA, INC. — Full financial report (2025 Y)", "documentId": "D-f70506775ed346c3a83059b1c1551e43" }, { "id": "T13228864", "href": "https://app.finbar.com/go?id=T13228864", "label": "ILLUMINA, INC. — Full financial report (2025 Y)", "documentId": "D-f70506775ed346c3a83059b1c1551e43" }, { "id": "P48863762", "href": "https://app.finbar.com/go?id=P48863762", "label": "ILLUMINA, INC. — Full financial report (2025 Y)", "documentId": "D-f70506775ed346c3a83059b1c1551e43" }, { "id": "P100287799", "href": "https://app.finbar.com/go?id=P100287799", "label": "ILLUMINA, INC. — Full financial report (2025 Y)", "documentId": "D-f70506775ed346c3a83059b1c1551e43" }, { "id": "https://www.illumina.com/systems/sequencing-platforms/novaseq-x-plus/specifications.html", "href": "https://www.illumina.com/systems/sequencing-platforms/novaseq-x-plus/specifications.html", "label": "www.illumina.com" }, { "id": "https://www.illumina.com/systems/sequencing-platforms/miseq-i100/specifications.html", "href": "https://www.illumina.com/systems/sequencing-platforms/miseq-i100/specifications.html", "label": "www.illumina.com" }, { "id": "https://www.illumina.com/systems/sequencing-platforms/nextseq-1000-2000.html", "href": "https://www.illumina.com/systems/sequencing-platforms/nextseq-1000-2000.html", "label": "www.illumina.com" }, { "id": "https://emea.illumina.com/products/by-type/sequencing-kits.html", "href": "https://emea.illumina.com/products/by-type/sequencing-kits.html", "label": "emea.illumina.com" }, { "id": "P84488577", "href": "https://app.finbar.com/go?id=P84488577", "label": "ILLUMINA, INC. — Full financial report (2025 Y)", "documentId": "D-f70506775ed346c3a83059b1c1551e43" }, { "id": "P107729460", "href": "https://app.finbar.com/go?id=P107729460", "label": "ILLUMINA, INC. — Full financial report (2025 Y)", "documentId": "D-f70506775ed346c3a83059b1c1551e43" }, { "id": "P57346774", "href": "https://app.finbar.com/go?id=P57346774", "label": "ILLUMINA, INC. — Full financial report (2025 Y)", "documentId": "D-f70506775ed346c3a83059b1c1551e43" }, { "id": "https://www.illumina.com/services/instrument-services.html", "href": "https://www.illumina.com/services/instrument-services.html", "label": "www.illumina.com" }, { "id": "T12402378", "href": "https://app.finbar.com/go?id=T12402378", "label": "ILLUMINA, INC. — Full financial report (2025 Y)", "documentId": "D-f70506775ed346c3a83059b1c1551e43" }, { "id": "T16635174", "href": "https://app.finbar.com/go?id=T16635174", "label": "ILLUMINA, INC. — Full financial report (2026 Q 2)", "documentId": "D-43377a94c0d14d998012b2a23924dfdd" }, { "id": "T4802710", "href": "https://app.finbar.com/go?id=T4802710", "label": "ILLUMINA, INC. — Full financial report (2025 Y)", "documentId": "D-f70506775ed346c3a83059b1c1551e43" }, { "id": "P8036207", "href": "https://app.finbar.com/go?id=P8036207", "label": "ILLUMINA, INC. — Full financial report (2025 Y)", "documentId": "D-f70506775ed346c3a83059b1c1551e43" }, { "id": "T728442", "href": "https://app.finbar.com/go?id=T728442", "label": "ILLUMINA, INC. — Full financial report (2025 Y)", "documentId": "D-f70506775ed346c3a83059b1c1551e43" }, { "id": "P30921653", "href": "https://app.finbar.com/go?id=P30921653", "label": "ILLUMINA, INC. — Full financial report (2025 Y)", "documentId": "D-f70506775ed346c3a83059b1c1551e43" }, { "id": "P66846235", "href": "https://app.finbar.com/go?id=P66846235", "label": "ILLUMINA, INC. — Full financial report (2025 Y)", "documentId": "D-f70506775ed346c3a83059b1c1551e43" }, { "id": "P119549994", "href": "https://app.finbar.com/go?id=P119549994", "label": "ILLUMINA, INC. — Full financial report (2025 Y)", "documentId": "D-f70506775ed346c3a83059b1c1551e43" }, { "id": "P4189507", "href": "https://app.finbar.com/go?id=P4189507", "label": "ILLUMINA, INC. — Full financial report (2025 Y)", "documentId": "D-f70506775ed346c3a83059b1c1551e43" }, { "id": "https://www.illumina.com/company/news-center/press-releases/2023/c149a755-79b1-4040-b0f5-4aa7d6b15320.html", "href": "https://www.illumina.com/company/news-center/press-releases/2023/c149a755-79b1-4040-b0f5-4aa7d6b15320.html", "label": "www.illumina.com" }, { "id": "https://www.illumina.com/content/dam/illumina-marketing/documents/company/illumina-source-book-september-2020.pdf", "href": "https://www.illumina.com/content/dam/illumina-marketing/documents/company/illumina-source-book-september-2020.pdf", "label": "www.illumina.com" }, { "id": "https://www.illumina.com/science/technology/next-generation-sequencing/illumina-sequencing-history.html", "href": "https://www.illumina.com/science/technology/next-generation-sequencing/illumina-sequencing-history.html", "label": "www.illumina.com" }, { "id": "https://emea.illumina.com/company/news-center/press-releases/2010/1374339.html", "href": "https://emea.illumina.com/company/news-center/press-releases/2010/1374339.html", "label": "emea.illumina.com" }, { "id": "https://emea.illumina.com/company/news-center/press-releases/2011/1515239.html", "href": "https://emea.illumina.com/company/news-center/press-releases/2011/1515239.html", "label": "emea.illumina.com" }, { "id": "https://emea.illumina.com/company/news-center/press-releases/2013/1787718.html", "href": "https://emea.illumina.com/company/news-center/press-releases/2013/1787718.html", "label": "emea.illumina.com" }, { "id": "https://emea.illumina.com/company/news-center/press-releases/2016/2127903.html", "href": "https://emea.illumina.com/company/news-center/press-releases/2016/2127903.html", "label": "emea.illumina.com" }, { "id": "https://www.illumina.com/company/news-center/press-releases/press-release-details.html?newsid=26816", "href": "https://www.illumina.com/company/news-center/press-releases/press-release-details.html?newsid=26816", "label": "www.illumina.com" }, { "id": "P21859633", "href": "https://app.finbar.com/go?id=P21859633", "label": "ILLUMINA, INC. — Full financial report (2023 Y)", "documentId": "D-62dacc8131fc498c997b8e8714958bc9" }, { "id": "P23498362", "href": "https://app.finbar.com/go?id=P23498362", "label": "ILLUMINA, INC. — Full financial report (2024 Y)", "documentId": "D-b97657eb444e4b21a443e533f606d67e" }, { "id": "https://www.illumina.com/company/news-center/press-releases/press-release-details.html?newsid=59115c59-ad0c-49dd-86d3-a9c00df0c847", "href": "https://www.illumina.com/company/news-center/press-releases/press-release-details.html?newsid=59115c59-ad0c-49dd-86d3-a9c00df0c847", "label": "www.illumina.com" } ] }